TSND-201 Shows Promise as a Novel Treatment for Post-Traumatic Stress Disorder
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on June 15th, 2026
|
Currently, only two medications - paroxetine and sertraline - are approved by the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD). Both are selective serotonin reuptake inhibitors, and while they can be beneficial for some patients, their effectiveness is often modest and treatment may be limited by adverse effects. Given the need for new therapeutic options, a recent study published in the Journal of the American Medical Association evaluated the efficacy and safety of TSND-201, a novel neuroplastogen, for the treatment of PTSD.
Funding Source(s): Transcend Therapeutics
The phase 2 clinical trial enrolled 65 adults with a mean age of 43.7 years who met DSM-5 diagnostic criteria for post-traumatic stress disorder. Participants had a mean baseline Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 45.9 and had been living with symptoms for an average of 19 years. Sexual trauma was the most common precipitating event, accounting for 44.6% of cases, while military-related trauma accounted for 7.7%. All participants had previously received treatment, with 66.2% having undergone pharmacotherapy and 76.9% having participated in psychotherapy.
Participants were randomly assigned to receive either placebo or TSND-201. Treatment began with a 150 mg oral dose followed by weekly doses of 100 mg. TSND-201 is a rapid-acting β-ketone analog of 3,4-methylenedioxymethamphetamine (MDMA) that promotes the release of serotonin, norepinephrine, and dopamine. Preclinical and early clinical studies have suggested that the compound may have antidepressant and anxiolytic properties, while also enhancing fear extinction and memory processing—mechanisms that may be particularly relevant in PTSD.
After 64 days of treatment, patients receiving TSND-201 experienced significantly greater improvement in PTSD symptoms than those receiving placebo. The mean reduction in CAPS-5 score was 23.3 points in the TSND-201 group, compared with 13.6 points in the placebo group. Improvements were observed across all major symptom domains, including intrusive memories, avoidance behaviors, negative changes in cognition and mood, and heightened arousal or reactivity. By the end of the study, more than 60% of participants treated with TSND-201 no longer met diagnostic criteria for PTSD, compared with approximately 30% of those receiving placebo. However, treatment was associated with a higher frequency of adverse events, including decreased appetite, dizziness, elevated blood pressure, dry mouth, and muscle tightness. These findings suggest that TSND-201 may represent a promising new therapeutic approach for PTSD, although larger and longer-term studies will be needed to confirm its efficacy and safety.
Funding Source(s): Transcend Therapeutics
The phase 2 clinical trial enrolled 65 adults with a mean age of 43.7 years who met DSM-5 diagnostic criteria for post-traumatic stress disorder. Participants had a mean baseline Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 45.9 and had been living with symptoms for an average of 19 years. Sexual trauma was the most common precipitating event, accounting for 44.6% of cases, while military-related trauma accounted for 7.7%. All participants had previously received treatment, with 66.2% having undergone pharmacotherapy and 76.9% having participated in psychotherapy.
Participants were randomly assigned to receive either placebo or TSND-201. Treatment began with a 150 mg oral dose followed by weekly doses of 100 mg. TSND-201 is a rapid-acting β-ketone analog of 3,4-methylenedioxymethamphetamine (MDMA) that promotes the release of serotonin, norepinephrine, and dopamine. Preclinical and early clinical studies have suggested that the compound may have antidepressant and anxiolytic properties, while also enhancing fear extinction and memory processing—mechanisms that may be particularly relevant in PTSD.
After 64 days of treatment, patients receiving TSND-201 experienced significantly greater improvement in PTSD symptoms than those receiving placebo. The mean reduction in CAPS-5 score was 23.3 points in the TSND-201 group, compared with 13.6 points in the placebo group. Improvements were observed across all major symptom domains, including intrusive memories, avoidance behaviors, negative changes in cognition and mood, and heightened arousal or reactivity. By the end of the study, more than 60% of participants treated with TSND-201 no longer met diagnostic criteria for PTSD, compared with approximately 30% of those receiving placebo. However, treatment was associated with a higher frequency of adverse events, including decreased appetite, dizziness, elevated blood pressure, dry mouth, and muscle tightness. These findings suggest that TSND-201 may represent a promising new therapeutic approach for PTSD, although larger and longer-term studies will be needed to confirm its efficacy and safety.